Gary S. Stetz, Interim CEO at Hepion Pharmaceuticals, Inc. (HEPA), bought 1,250,000 shares at $0.04 ($50K) on 2026-04-21, disclosed to the SEC on 2026-04-27.
Interim CEO Gary S. Stetz acquired 1.25 million shares at $0.04, representing the largest insider purchase in Hepion's history. This substantial capital commitment by C-suite leadership signals strong conviction in the company's future value.
The stock is currently trading at $0.3181, up 3% over the last 30 days and trading at its 52-week high of $0.3181.
A cluster of 2 other insiders purchased shares in the last 30 days, suggesting a broader trend of insider accumulation.
The stock faces elevated risk with a short interest of 4.1%, which could drive volatility if the price fails to sustain its recent momentum.
Something here stands out, but not much.
| Filing → |
| CNTN | SELL | 2026-05-27 | $258K | — | Filing → |
| BCBP | BUY | 2018-03-14 | $8K | — | Filing → |
| BCBP | BUY | 2017-10-25 | $26K | — | Filing → |